Showing results (1191-1200 of 2,812) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|September 21, 2017
High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directionsStephen Marabondo, Howard L KaufmanExpert Opinion on Drug Safety|September 8, 2017
Non-chemotherapy drug-induced neutropenia - an updateEmmanuel Andrès, Rachel Mourot-CottetExpert Opinion on Drug Safety|September 1, 2017
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, et al.Expert Opinion on Drug Safety|September 12, 2017
Safety issues associated with using medication to treat overactive bladderGeorge Araklitis, Linda CardozoExpert Opinion on Drug Safety|March 9, 2016
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studiesMartin C Michel, Stavros GravasExpert Opinion on Drug Safety|December 10, 2015
The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysisGiovanni Corona, Giulia Rastrelli, Andrea Burri, et al.Expert Opinion on Drug Safety|November 20, 2015
Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitisLudger Klimek, Jean Bousquet, David PriceExpert Opinion on Drug Safety|December 19, 2015
A Safety Evaluation of Cangrelor in Patients Undergoing PCIFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.Expert Opinion on Drug Safety|July 28, 2015
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature reviewFrancesco Benvenuti, Mariele Gatto, Maddalena Larosa, et al.Expert Opinion on Drug Safety|November 27, 2015
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluationDaisuke Yabe, Yutaka SeinoPageof 282